CBS 2019
CBSMD教育中心
English

动脉粥样硬化性心血管疾病

科研文章

荐读文献

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel Primary Prevention Trial Designs Using Coronary Imaging: A National Heart, Lung, and Blood Institute Workshop Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes The Year in Cardiovascular Medicine 2020: Coronary Prevention: Looking back on the Year in Cardiovascular Medicine for 2020 in the field of coronary prevention is Professor Ramon Estruch, Dr Luis Ruilope, and Professor Francesco Cosentino. Mark Nicholls meets them Value of Coronary Artery Calcium Scanning in Association With the Net Benefit of Aspirin in Primary Prevention of Atherosclerotic Cardiovascular Disease Association Between Depressive Symptoms and Incident Cardiovascular Diseases Haptoglobin genotype: a determinant of cardiovascular complication risk in type 1 diabetes Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular DiseaseA Prespecified Analysis From the FOURIER Trial The sinus venosus contributes to coronary vasculature through VEGFC-stimulated angiogenesis Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|<<... 5 6 7 8 9 10 11 ...>>|

Clinical Trial2011;364:818-28.

JOURNAL：N Engl J Med. Article Link

Long-term effects of intensive glucose lowering on cardiovascular outcomes

ACCORD Study Group, HC Gerstein, ME Miller et al. Keywords: T2DM; intensive glucose lowering; cardiovascular effect

Full Text PDF

网站资料更新中...
>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top